Advertisement

Renal Cancer Vaccines

  • Hyung L. Kim
  • Barbara J. Gitlitz
  • Robert A. Figlin
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

It is estimated that approx 30,000 new cases of renal cell carcinoma (RCC) were diagnosed in 2002 (1). Approximately 20–30% of patients with RCC present with metastatic disease and their overall median survival is 6–8 mo (2). Although, metastatic RCC carries a poor prognosis, in a small subset of patients the disease has a variable course (3). Oliver et al. observed 73 patients with metastatic RCC without treatment (4). In this series, 4% had complete and spontaneous regression of disease and 3% had partial regression of disease. Furthermore, 5% had stable disease with no evidence of progression for more than 12 mo. There are also numerous cases of patients who recur with metastatic RCC over 10 yr after undergoing a nephrectomy for apparently localized disease. It is presumed from these observations that the immune system plays a key role in cases of spontaneous regression and durable remissions of RCC.

Keywords

Epidermal Growth Factor Receptor Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Autologous Tumor Autologous Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int 2001; 88:818–824.PubMedCrossRefGoogle Scholar
  3. 3.
    Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352:1691–1696.PubMedCrossRefGoogle Scholar
  4. 4.
    Oliver RT, Miller RM, Mehta A, Barnett MJ. A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol Biother 1988: 1:14–20.PubMedGoogle Scholar
  5. 5.
    Bukowski RM. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 2000; 27:204–212.PubMedGoogle Scholar
  6. 6.
    Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997; 3(Suppl 1):S70-S72.Google Scholar
  7. 7.
    Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161:381–386.PubMedCrossRefGoogle Scholar
  8. 8.
    Franzke A, Peest D, Probst-Kepper M, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999; 17:529–533.PubMedGoogle Scholar
  9. 9.
    Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38:489–494.PubMedCrossRefGoogle Scholar
  10. 10.
    Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9:802–811.PubMedGoogle Scholar
  11. 11.
    Sargent ER, Gomella LG, Belldegrun A, Linehan WM, Kasid A. Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol 1989; 142:1364–1368.PubMedGoogle Scholar
  12. 12.
    Weidner U, Peter S, Strohmeyer T, Hussnatter R, Ackermann R, Sies H. Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res 1990; 50:4504–4509.PubMedGoogle Scholar
  13. 13.
    Yoshida K, Tosaka A, Takeuchi S, Kobayashi N. Epidermal growth factor receptor content in human renal cell carcinomas. Cancer 1994; 73:1913–1918.PubMedCrossRefGoogle Scholar
  14. 14.
    Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15:1529–1537.PubMedGoogle Scholar
  15. 15.
    Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4:2729–2739.PubMedGoogle Scholar
  16. 16.
    Figlin R, Belldegrun A, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002:Abstract 35.Google Scholar
  17. 17.
    Hoffman DM, Gitlitz BJ, Belldegrun A, Figlin RA. Adoptive cellular therapy. Semin Oncol. 2000; 27:221–233.PubMedGoogle Scholar
  18. 18.
    Hamada I, Kato M, Yamasaki T, et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res 2002; 22:4281–4284.PubMedGoogle Scholar
  19. 19.
    Thumher M, Radmayr C, Ramoner R, et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 1996; 68:1–7.CrossRefGoogle Scholar
  20. 20.
    Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998; 4:585–593.PubMedGoogle Scholar
  21. 21.
    Mulders P, Tso CL, Gitlitz B, et al. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 1999; 5:445–454.PubMedGoogle Scholar
  22. 22.
    Radmayr C, Bock G, Hobisch A, Klocker H, Bartsch G, Thurnher M. Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients. Int J Cancer 1995; 63:627–632.PubMedCrossRefGoogle Scholar
  23. 23.
    Gitlitz B, Figlin R, Kiertscher S, Moldawer N, Rosen F, Roth MD. A phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for cancer. J Immunother 2003, in press.Google Scholar
  24. 24.
    Roth MD, Gitlitz BJ, Kiertscher SM, et al. Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res 2000; 60:1934–1941.PubMedGoogle Scholar
  25. 25.
    Gitlitz B, Belldegrun A, Zisman A, et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma, submitted 2003.Google Scholar
  26. 26.
    Marten A, Flieger D, Renoth S, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002; 51:637–644.PubMedCrossRefGoogle Scholar
  27. 27.
    Holtl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002; 8:3369–3376.PubMedGoogle Scholar
  28. 28.
    Shimizu K, Fields RC, Giedlin M, Mule JJ. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 1999; 96: 2268–2273.PubMedCrossRefGoogle Scholar
  29. 29.
    Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002; 25:500–508.PubMedCrossRefGoogle Scholar
  30. 30.
    Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6:332–336.PubMedCrossRefGoogle Scholar
  31. 31.
    Tuffs A. Doubts raised over cancer vaccine study. BMJ 2001; 323:184.CrossRefGoogle Scholar
  32. 31a.
    Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003; 63:2127–2133.PubMedGoogle Scholar
  33. 32.
    Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000; 85:865–870.PubMedCrossRefGoogle Scholar
  34. 33.
    Vissers JL, De Vries IJ, Schreurs MW, et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999; 59:5554–5559.PubMedGoogle Scholar
  35. 34.
    Hernandez JM, Bui MH, Han K-R, et al. Novel kidney cancer immunotherapy based on the granulocytemacrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res 2003; 9:1906–1919.PubMedGoogle Scholar
  36. 35.
    Amato RJ, Murray L, Wood L, Savary C, Tomasovic S, Reitsma D. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor derived heat shock protein-peptide complex 96 (HSPP-96) vaccine. Proc Am Soc Clin Oncol 1999:Abstract.Google Scholar
  37. 36.
    Cohen L, de Moor C, Parker PA, Amato RJ. Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine. Urol Oncol 2002; 7:119–124.PubMedCrossRefGoogle Scholar
  38. 37.
    Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57:1537–1546.PubMedGoogle Scholar
  39. 38.
    Kawai K, Tani K, Asano S, Akaza H. Ex vivo gene therapy using granulocyte-macrophage colonystimulating factor-transduced tumor vaccines. Mol Urol 2000; 4:43–46.PubMedCrossRefGoogle Scholar
  40. 39.
    Meyers ML, Minasian L, Motzer RJ, et al. Immunization with HLA-A2 matched allogeneic tumor cells that secrete interleukin-2 of (IL-2) patients with metastatic melanoma or metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 1997:Abstract 441.Google Scholar
  41. 40.
    Antonia SJ, Seigne J, Diaz J, et al. Phase I trial of a B7–1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 2002; 167:1995–2000.PubMedCrossRefGoogle Scholar
  42. 41.
    Rini BI, Selk LM, Vogelzang NJ. Phase Istudy of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999; 5:2766–2772.PubMedGoogle Scholar
  43. 42.
    Hoffman DM, Figlin RA. Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol 2000; 18:152–156.PubMedCrossRefGoogle Scholar
  44. 43.
    Kaushik A. Leuvectin Vical Inc. Curr Opin Investig Drugs 2001; 2:976–981.PubMedGoogle Scholar
  45. 44.
    Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997; 15:796–807.PubMedGoogle Scholar
  46. 45.
    Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 2003; 21:884–890.PubMedCrossRefGoogle Scholar
  47. 46.
    Tanigawa K, Takeshita N, Eickhoff GA, Shimizu K, Chang AE. Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines. J Immunother 2001; 24:493–501.PubMedCrossRefGoogle Scholar
  48. 47.
    Li Q, Yu B, Grover AC, Zeng X, Chang AE. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies. J Immunother 2002; 25:304–313.PubMedCrossRefGoogle Scholar
  49. 48.
    Meijer SL, Dols A, Urba WJ, et al. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J Immunother 2002; 25:359–372.PubMedCrossRefGoogle Scholar
  50. 49.
    Mulders P, Tso CL, Pang S, et al. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. J Immunother 1998; 21:170–180.PubMedCrossRefGoogle Scholar
  51. 50.
    Azuma T, Hone S, Tomita K, et al. Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. Int J Urol 2002; 9:340–346.PubMedCrossRefGoogle Scholar
  52. 51.
    Finke JH, Rayman P, George R, et al. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression. Clin Cancer Res 2001; 7:940s–946s.Google Scholar
  53. 52.
    Ng CS, Novick AC, Tannenbaum CS, Bukowski RM, Finke JH. Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression. Urology 2002: 59:9–14.PubMedCrossRefGoogle Scholar
  54. 53.
    Rayman P, Uzzo RG, Kolenko V, et al. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape. Cancer J Sci Am 2000; 6(Suppl 1):581-S87.Google Scholar
  55. 54.
    Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003; 22:847–852.PubMedCrossRefGoogle Scholar
  56. 55.
    Unwin RD, Harnden P, Pappin D, Rahman D, Whelan P, Craven RA, Selby PJ, Banks RE. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003; 3:45–55.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Hyung L. Kim
  • Barbara J. Gitlitz
  • Robert A. Figlin

There are no affiliations available

Personalised recommendations